Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueInventory Average

RedHill Biopharma (RDHL) EBIT Margin (2016 - 2023)

Historic EBIT Margin for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to 2992.87%.

  • RedHill Biopharma's EBIT Margin rose 29429500.0% to 2992.87% in Q2 2023 from the same period last year, while for Jun 2023 it was 122.98%, marking a year-over-year increase of 79700.0%. This contributed to the annual value of 181.69% for FY2024, which is 3751300.0% down from last year.
  • Per RedHill Biopharma's latest filing, its EBIT Margin stood at 2992.87% for Q2 2023, which was up 29429500.0% from 808.0% recorded in Q1 2023.
  • RedHill Biopharma's 5-year EBIT Margin high stood at 2992.87% for Q2 2023, and its period low was 808.0% during Q1 2023.
  • Its 5-year average for EBIT Margin is 336.14%, with a median of 90.03% in 2020.
  • As far as peak fluctuations go, RedHill Biopharma's EBIT Margin tumbled by -15231400bps in 2021, and later soared by 29429500bps in 2023.
  • Over the past 5 years, RedHill Biopharma's EBIT Margin (Quarter) stood at 739.87% in 2019, then tumbled by -88bps to 91.83% in 2020, then crashed by -798bps to 641.43% in 2021, then rose by 8bps to 591.81% in 2022, then skyrocketed by 606bps to 2992.87% in 2023.
  • Its last three reported values are 2992.87% in Q2 2023, 808.0% for Q1 2023, and 591.81% during Q4 2022.